- Policy
- Avastin additional coverage approved for colorectal cancer
- by Lee, Hye-Kyung Feb 18, 2020 06:35am
- Combination therapy of Avastin (bevacizumab) plus irinotecan plus low-dose capecitabine (mCAPIRI)’ treating metastatic colorectal cancer would receive insurance benefit from Mar. 1. Moreover, indications to treat patients with stage IIB or later mycosis fungoides, primary cutaneous anaplastic large cell lymphoma (pcALCL), or Séza
- Policy
- The MFDS collects 900 Metformins & tests for carcinogens
- by Lee, Tak-Sun Feb 17, 2020 06:26am
- The MFDS is conducting extensive testing of carcinogens in the drug 'Metformin', which is used as the primary treatment for type II diabetes. It is known that as many as 900 items to be inspected. As the US FDA announced the results of the survey yesterday, the MFDS is expected to speed up the survey in order to advance the publication dat
- Policy
- The TF agrees on COVID-19 treatment, 2 tabs of Kaletra BID
- by Kim, Jung-Ju Feb 17, 2020 06:25am
- Although the development of 'COVID-19' treatment has not been completed, the principle has been established that the treatment can be considered by administering two tablets of Abbvie’s Kaletra twice a day. Chloroquine, an antimalarial drug, is also considered, but not domestically distributed. Instead, Hydroxychloroquine, which is used a
- Policy
- “Genetic testing not required for reimbursed Soliris use"
- by Lee, Hye-Kyung Feb 17, 2020 06:25am
- Health Insurance Review and Assessment Service (HIRA) has disseminated a press release to explain a news article raising issues on preliminary review on atypical hemolytic uremic syndrome (aHUS) treatment Soliris injection (eculizumab). Apparently, a news article has reported the government deferring and rejecting preliminary approval o
- Policy
- Nocdurna to receive reimbursement from next month
- by Kim, Jung-Ju Feb 17, 2020 06:25am
- Ferring Korea’s Nocdurna sublingual tablet (desmopressin acetate) is to get listed for reimbursement next month. On Feb. 12, Ministry of Health and Welfare (MOHW) issued an administrative notice on amending ‘Pharmaceutical Reimbursement Listing Standard and Method,’ and plans to collect public opinions until Feb. 20. Ministry of Fo
- Policy
- Opposition buys time with Covid-19 delaying HIPDC meeting
- by Lee, Jeong-Hwan Feb 14, 2020 06:35am
- Due to the Covid-19 outbreak, the pilot program for providing reimbursement on Korean herbal medicine would inevitably be delayed. Initially, the government was planning to particularly discuss of coverage on herbal medicine at a Health Insurance Policy Deliberation Committee’s (HIPDC) subcommittee meeting, right as Korean Herbal Medicine Re
- Policy
- It is time to support quarantine with the 'COVID-19'
- by Lee, Jeong-Hwan Feb 14, 2020 06:35am
- The Democratic Party's COVID-19 Countermeasures Committee urged an agreement on the opposition party on the composition of parliament. With the intention that the national disaster should not be controversial due to naming conflicts such as Wuhan pneumonia, it is a suggestion that the government should support joint efforts on the preventi
- Policy
- “HIRA’s open ears and hearts for pharmaceutical industry"
- by Lee, Hye-Kyung Feb 14, 2020 06:35am
- "The Pharmaceutical Management Department had to move to Wonju, as the construction of second headquarter building of Health Insurance Review and Assessment Service has been completed. But its door is open. We plan to have our ears and hearts opened to the pharmaceutical industry." Kim Ae-ryun, appointed as a director of Pharmaceutical Manage
- Policy
- Constipation drug Rucalo gets coverage but with condition
- by Lee, Hye-Kyung Feb 14, 2020 06:34am
- A new reimbursement standard has been added as Yooyoung Pharmaceutical’s chronic constipation treatment Rucalo tablet (prucalopride succinate) has been listed for reimbursement. Korea’s Ministry of Health and Welfare (MOHW) announced on Feb. 6 the authority has decided to grant reimbursement on Rucalo tablet by partially amending ‘Det
- Policy
- COVID-19 primary antivirals Kaletra·Chloroquine recommended
- by Lee, Jeong-Hwan Feb 13, 2020 06:28am
- The central clinical TF will recommend antiretroviral agents Kaletra, antimalarial agents Chloroquine, and Hydroxychloroquine as the primary antiviral drugs for COVID-19. Ribavirin and Interferon, which are mentioned as COVID-19 drugs, have relatively high side effects and are not recommended as primary antiviral drugs. In particular, some
